Advertisement
Advertisement
ABCL
AbCellera Biologics Inc. Common Shares
3.29
USDSponsored
-0.10
-2.80%
Apr 07, 15:21 UTC -4
Open
ABCL Earnings Reports
Positive Surprise Ratio
ABCL beat 9 of 21 last estimates.
43%
Next Report
Date of Next Report
May 10, 2026
Estimate for Q1 26 (Revenue/ EPS)
$5.79M
/-$0.19
Implied change from Q4 25 (Revenue/ EPS)
-87.10%
/+533.33%
Implied change from Q1 25 (Revenue/ EPS)
+36.67%
/+26.67%
AbCellera Biologics Inc. Common Shares earnings per share and revenue
On Feb 24, 2026, ABCL reported earnings of -0.03 USD per share (EPS) for Q4 25, beating the estimate of -0.17 USD, resulting in a 83.10% surprise. Revenue reached 44.85 million, compared to an expected 6.19 million, with a 625.19% difference. The market reacted with a -0.93% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.19 USD, with revenue projected to reach 5.79 million USD, implying an increase of 533.33% EPS, and decrease of -87.10% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Forte Biosciences, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.23
Actual
-$1.39
Surprise
-12.31%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
MiNK Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.83
Actual
-$0.55
Surprise
+33.64%
Femasys Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.80%
Tevogen Bio Holdings Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$2.04
Actual
-$1.45
Surprise
+28.92%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$1.99
Surprise
-66.18%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
FAQ
What were AbCellera Biologics Inc. Common Shares's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, AbCellera Biologics Inc. Common Shares reported EPS of -$0.03, beating estimates by 83.1%, and revenue of $44.85M, 625.19% above expectations.
How did the market react to AbCellera Biologics Inc. Common Shares's Q4 2025 earnings?
The stock price moved down -0.93%, changed from $3.22 before the earnings release to $3.19 the day after.
When is AbCellera Biologics Inc. Common Shares expected to report next?
The next earning report is scheduled for May 10, 2026.
What are the forecasts for AbCellera Biologics Inc. Common Shares's next earnings report?
Based on 7
analysts, AbCellera Biologics Inc. Common Shares is expected to report EPS of -$0.19 and revenue of $5.79M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement